Press Releases
Abpro Forms Strategic Partnership to Advance Two Bispecific Antibody Candidates in Asian Markets
Abpro, a biotechnology company dedicated to developing next-generation antibody therapeutics to improve the lives of patients with severe and life-threatening diseases, announced the formation of a strategic partnership to advance two bispecific antibodies in key Asian markets including Greater...
Press Releases
FDA approves GSKs Advil Dual Action with Acetaminophen for over-the-counter use in the United States
GlaxoSmithKline announced that the U.S. FDA has approved Advil Dual Action with Acetaminophen as an over-the-counter (OTC) product for pain relief. The exclusive formula is now the first FDA-approved OTC combination of ibuprofen and acetaminophen in the United States...
Drug Research
Catalent Announces Supplying Blueprint Medicines Precision Therapy AYVAKIT
Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene and cell therapies, and consumer health products, welcomes the announcement by Blueprint Medicines Corporation that the U.S. Food and Drug Administration (FDA)...
Clinical Trials
Rare Disease Patient Platform Raremark Partners With TriNetX
TriNetX, the global health research network that revolutionizes clinical research and enables discoveries through the generation of real-world evidence (RWE), announced that Raremark, a patient-data platform focused on rare disease, has partnered with the TriNetX network to bring more...
Press Releases
Signant Health invests for growth with the opening of its new Philadelphia-area office
Signant Health, an industry-leading clinical research technology and solutions company, is proud to announce that it has officially opened a new, leading edge office facility in Blue Bell, Pennsylvania. Construction on the new office, which is the largest workplace...
Press Releases
Sun Pharma Launches RIOMET ER Oral Suspension in the U.S.
Sun Pharmaceutical Industries Ltd. announced that one of its whollyowned subsidiaries has launched Riomet ER™ in the U.S. as an adjunct to diet and exercise to improve glycemic control in patients 10 years of age and older with type...
Press Releases
Dulaglutide Receives FDA Approval for Reducing MACE in Type 2 Diabetics
The U.S. FDA has approved Trulicity® (dulaglutide) for the reduction of major adverse cardiovascular events (MACE) in adults with type 2 diabetes who have established cardiovascular (CV) disease or multiple cardiovascular risk factors. This decision makes Eli Lilly and...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.